HPV Research

  • Recent Studies
    • AHCC Preclinical Studies
    • AHCC Pilot Study in HPV+ Women
  • Current Research Focus
    • Continuation of Pilot study to evaluate alternative dosing of AHCC supplementation
    • Phase II double-blind, placebo-controlled randomized to evaluate efficacy of AHCC for eradication of high-risk HPV infections in women with persistent HPV infection (Note even those randomized to placebo will receive AHCC after completion of study primary endpoint at 12 months)
      • We are recruiting healthy women 30 years of age or older that have confirmed persistent HPV infections (greater than two years of HPV-positive tests)
      • If interested please email Principal Investigator: Dr. Judith A. Smith
  • FAQs about HPV and AHCC
    1. What is HPV?
      Answer: The human papillomavirus (HPV) is a virus that has been detected in more than 99 percent of cervical cancer patients. According to the Centers for Disease Control and Prevention, several other cancers are related to HPV, including 95 percent of anal cancers, 60 percent of oropharyngeal, 65 percent of vaginal cancers, 50 percent of vulvar cancers and 35 percent of penile cancers.
    2. What is AHCC?
      Answer: AHCC is a nutritional supplement that works as an immunotherapy. Human and preclinical studies have shown that AHCC increases the number and/or activity of Natural Killer (NK) cells, dendritic cells and cytokines, which help the body fight off infections and block tumor growth.
      Read more information on AHCC